Mucosal Melanoma Clinical Trial
Official title:
A Multicenter, Single-arm, Open, Phase II Clinical Study on the Efficacy and Safety of Toripalimab(JS001) After Chemotherapy in Combination With Endostar in Patients With Unresectable Locally Advanced or Metastatic Mucosal Melanoma
This study is a multicenter, single-arm, open, phase Ⅱ clinical study to evaluate the safety and efficacy of Toripalimab(JS001) monoclonal injection after chemotherapy in combination with Endostar for Locally Advanced or Metastatic Mucosal Melanoma.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01961115 -
Epacadostat and Vaccine Therapy in Treating Patients With Stage III-IV Melanoma
|
Phase 2 | |
| Active, not recruiting |
NCT03241186 -
Ipilimumab and Nivolumab as Adjuvant Treatment of Mucosal Melanoma
|
Phase 2 | |
| Withdrawn |
NCT05482074 -
Olaparib in Unresectable/Metastatic Melanoma With BRCA1/2
|
Phase 2 | |
| Completed |
NCT02858869 -
Pembrolizumab and Stereotactic Radiosurgery for Melanoma or Non-Small Cell Lung Cancer Brain Metastases
|
Phase 1 | |
| Completed |
NCT04551352 -
A Study of RO7293583 in Participants With Unresectable Metastatic Tyrosinase Related Protein 1 (TYRP1)-Positive Melanomas
|
Phase 1 | |
| Active, not recruiting |
NCT03033576 -
Testing Treatment With Ipilimumab and Nivolumab Compared to Treatment With Ipilimumab Alone in Advanced Melanoma
|
Phase 2 | |
| Terminated |
NCT01166126 -
Temsirolimus/AZD 6244 for Treatment-naive With BRAF Mutant Unresectable Stage IV
|
Phase 2 | |
| Completed |
NCT02158520 -
Nab-Paclitaxel and Bevacizumab or Ipilimumab as First-Line Therapy in Treating Patients With Stage IV Melanoma That Cannot Be Removed by Surgery
|
Phase 2 | |
| Withdrawn |
NCT03220009 -
Nivolumab or Expectant Observation Following Ipilimumab, Nivolumab, and Surgery in Treating Patients With High Risk Localized, Locoregionally Advanced, or Recurrent Mucosal Melanoma
|
Phase 2 | |
| Recruiting |
NCT05628883 -
Proof of Concept of TBio-4101, Lymphodepleting Chemo, IL-2 for Relapsed/Refractory Melanoma
|
Phase 1 | |
| Active, not recruiting |
NCT03178123 -
The Study of JS001 Compared to High-Dose Interferon In Patients With Mucosal Melanoma That Has Been Removed by Surgery
|
Phase 2 | |
| Recruiting |
NCT04462965 -
Postoperative Adjuvant Treatment of Completely Resected Mucosal Melanoma Phase II Study
|
Phase 2 | |
| Recruiting |
NCT04830124 -
Nemvaleukin Alfa (ALKS 4230) Monotherapy in Patients With Advanced Cutaneous Melanoma or Advanced Mucosal Melanoma - ARTISTRY-6
|
Phase 2 | |
| Not yet recruiting |
NCT06424626 -
A Trial of AK104 or AK112 in Combination With Axitinib in Patients With Metastatic Mucosal Melanoma
|
Phase 1 | |
| Completed |
NCT00085189 -
Vaccine Therapy in Treating Patients With Stage IIC-IV Melanoma
|
Phase 2 | |
| Recruiting |
NCT05384496 -
Axitinib and Nivolumab for the Treatment of Mucosal Melanoma
|
Phase 2 | |
| Recruiting |
NCT06319196 -
Clear Me: Interception Trial to Detect and Clear Molecular Residual Disease in Patients With High-risk Melanoma
|
Phase 2 | |
| Completed |
NCT02126579 -
Phase I/II Trial of a Long Peptide Vaccine (LPV7) Plus TLR Agonists
|
Phase 1/Phase 2 | |
| Not yet recruiting |
NCT05545969 -
Neoadjuvant Pembrolizumab and Lenvatinib for Mucosal Melanoma
|
Phase 2 | |
| Recruiting |
NCT03986515 -
Apatinib Plus SHR1210 in Advanced Mucosal Melanoma
|
Phase 2 |